Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 194

Similar articles for PubMed (Select 11292199)

1.

Carboxypeptidase U at the interface between coagulation and fibrinolysis.

Schatteman K, Goossens F, Leurs J, Verkerk R, Scharpé S, Michiels JJ, Hendriks D.

Clin Appl Thromb Hemost. 2001 Apr;7(2):93-101. Review.

PMID:
11292199
2.

Proteolytic activation of purified human procarboxypeptidase U.

Schatteman KA, Goossens FJ, Scharpé SS, Hendriks DF.

Clin Chim Acta. 2000 Feb 25;292(1-2):25-40.

PMID:
10686274
3.

Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis.

Knecht W, Willemse J, Stenhamre H, Andersson M, Berntsson P, Furebring C, Harrysson A, Hager AC, Wissing BM, Hendriks D, Cronet P.

FEBS J. 2006 Feb;273(4):778-92.

PMID:
16441664
4.

Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma.

Schatteman KA, Goossens FJ, Scharpé SS, Neels HM, Hendriks DF.

Clin Chem. 1999 Jun;45(6 Pt 1):807-13.

5.

Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma.

Leurs J, Wissing BM, Nerme V, Schatteman K, Björquist P, Hendriks D.

Thromb Haemost. 2003 Feb;89(2):264-71.

PMID:
12574805
6.

Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.

Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, Strömqvist M, Hendriks D, Hamsten A.

Thromb Haemost. 2000 Sep;84(3):364-8.

PMID:
11019956
7.

Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis.

Schatteman KA, Goossens FJ, Scharpé SS, Hendriks DF.

Thromb Haemost. 1999 Dec;82(6):1718-21.

PMID:
10613660
8.

Fibrinolysis and the plasma carboxypeptidase.

Nesheim M.

Curr Opin Hematol. 1998 Sep;5(5):309-13. Review.

PMID:
9776208
9.

[Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].

Stasko J, Hudecek J, Kubisz P.

Vnitr Lek. 2004 Jan;50(1):36-44. Review. Slovak.

PMID:
15015228
10.

Thrombin-activatable fibrinolysis inhibitor.

Marx PF.

Curr Med Chem. 2004 Sep;11(17):2335-48. Review.

PMID:
15379716
11.

Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen.

Wang W, Hendriks DF, Scharpé SS.

J Biol Chem. 1994 Jun 3;269(22):15937-44.

12.

A role for procarboxypepidase U (TAFI) in thrombosis.

Willemse JL, Hendriks DF.

Front Biosci. 2007 Jan 1;12:1973-87. Review.

PMID:
17127436
14.

Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets.

Schadinger SL, Lin JH, Garand M, Boffa MB.

J Thromb Haemost. 2010 Nov;8(11):2523-9. doi: 10.1111/j.1538-7836.2010.04024.x.

PMID:
20723026
15.

Plasma carboxypeptidases as regulators of the plasminogen system.

Redlitz A, Tan AK, Eaton DL, Plow EF.

J Clin Invest. 1995 Nov;96(5):2534-8.

16.
17.

Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase.

Valnickova Z, Thøgersen IB, Potempa J, Enghild JJ.

J Biol Chem. 2007 Feb 2;282(5):3066-76. Epub 2006 Nov 30.

18.

An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis.

Heylen E, Willemse J, Hendriks D.

Front Biosci (Landmark Ed). 2011 Jun 1;16:2427-50. Review.

PMID:
21622187
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk